Q-omics provides the consensus-scored ZNF721 profile across patient tissues and cancer cell-line models. ZNF721 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZNF721 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ZNF721 RNA expression shows 21,308 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, LIHC, and UVM as cancer lineages where ZNF721 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF721 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF721 survival associations across molecular data types. ZNF721 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF721 RNA expression–survival associations across cancer types. High ZNF721 expression shows unfavorable associations in UVM and SARC, but favorable associations in SKCM, UCS, UCEC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZNF721 RNA expression.
This table summarizes ZNF721 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF721. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF721 shows lower tumor expression in THCA and higher tumor expression in LIHC, STAD, CHOL, BLCA and COAD. The LIHC box plot shows higher ZNF721 RNA expression in tumor versus normal tissue (log2 FC = +0.656, t-test p < 0.001).
This table shows molecular features associated with ZNF721 in patient tissues and cancer cell lines. In patient samples, ZNF721 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF721 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
